No Data
No Data
CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs
Revvity Earnings Preview: What to Expect
Revvity Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $135
Revvity To Go Ex-Dividend On October 18th, 2024 With 0.07 USD Dividend Per Share
Bernstein Adjusts Revvity Price Target to $150 From $145, Maintains Outperform Rating
No Data
No Data